retatrutide trial VisualAbstract: reduces body weight by 17.5% in patients with obesity The numbers from Lilly's Phase

Visit Doctronic.ai and create an account

A study from the Employee Benefit Research Institute (EBRI), supported by the Blue Cross Blue Shield Association and other partners, estimates that GLP-1 coverage would be a major premium driver for employer-provided coverage

adults are either currently using or considering a GLP-1 drug for weight loss

It targets three hormones (consider it a GLP-3), while tirzepatide targets two (and semaglutide targets one)

If you are a qualified lab or researcher, you can check out our top peptide vendor rankings

Despite this, there is a growing and concerning market for retatrutide and other research peptides sold online, often marketed to bodybuilders or individuals seeking weight loss